SCARNA17: A Potential Drug Target and Biomarker (G677769)

Target Name: SCARNA17

NCBI ID: G677769

SCARNA17

Other Name(s): Small Cajal body-specific RNA 17 | U91 | small Cajal body-specific RNA 17

SCARNA17: A Potential Drug Target and Biomarker

Small Cajal body-specific RNA 17 (SCARNA17) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. SCARNA17 is a key regulator of gene expression in cajal body neurons, which are responsible for the development and maintenance of motor neuron function. The study of SCARNA17 and its role in neural function has significant implications for our understanding of these debilitating diseases and for the development of new treatments.

The Cajal body is a pair of neurons that is responsible for controlling the movement of the muscles. These neurons are located in the brainstem and are responsible for the coordination of movement in response to sensory input. The Cajal body neurons are also known as the interneurons because they are located in the interruptive network, which is responsible for regulating the flow of information from the sensory neurons to the Cajal body neurons.

SCARNA17 is a non-coding RNA molecule that is produced by the Cajal body neurons. It is highly expressed in the Cajal body neurons and is expressed in a temporal pattern that is consistent with the onset of motor neuron dysfunction in neurodegenerative diseases.

The study of SCARNA17 and its role in motor neuron function has significant implications for our understanding of these debilitating diseases. Many neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of motor neurons. The loss of motor neurons in these diseases is thought to be caused by the dysfunction of the Cajal body neurons, which is characterized by the production of SCARNA17.

The study of SCARNA17 has also implications for the development of new treatments for neurodegenerative diseases. By targeting the Cajal body neurons and modulating their activity, it may be possible to treat neurodegenerative diseases and improve the quality of life for patients.

In addition to its potential as a drug target, SCARNA17 has also been identified as a potential biomarker for neurodegenerative diseases. The levels of SCARNA17 have been shown to be elevated in the brains of individuals with neurodegenerative diseases, and the levels have been linked to the severity of the disease. This suggests that SCARNA17 may be a useful biomarker for the diagnosis and progression of neurodegenerative diseases.

The study of SCARNA17 and its role in neural function is an active area of research, and there is a need for further studies to fully understand its function and potential as a drug target and biomarker. The identification of SCARNA17 as a potential drug target and biomarker has significant implications for the development of new treatments for neurodegenerative diseases and for our understanding of these debilitating conditions. Further research is needed to determine the full role of SCARNA17 in neural function and to explore its potential as a drug target and biomarker.

Protein Name: Small Cajal Body-specific RNA 17

The "SCARNA17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCARNA17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets